🏛️ Company factsSEC filings + FINRA official data
short activity above its recent average — bears adding.
Short volume
36%
20d avg 29.5% · shorts building
🐋 5%+ ownership filings (last 180d)
The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.
- 2026-04-28passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
No SEC filings for this ticker (non-US filer or newly listed)
🎯 Market expectations
Expectation reliability Low · 25/100Nasdaq analyst consensus · the pre-news baseline
There is no clear consensus on this stock (thin coverage or wide disagreement) — 'beating expectations' means little here.
- Jun 2026$2.63 vs $2.50+5.2%
- Mar 2026$2.58 vs $2.57+0.39%
- Dec 2025$1.06 vs $2.18-51.38%
- Sep 2025$2.38 vs $2.28+4.39%
Analyst estimates, not our forecast · not investment advice
What's moving this stock lately
1 direct · 0 2nd-order · 0 thematicRanked by impact strength · strength = estimated move × freshness decay (shorter-lived effects decay faster)
TAGRISSO (osimertinib) is the backbone of the combination; an expanded first-line market modestly supports AstraZeneca's lung-cancer franchise, though impact is small relative to its scale
Also named: HCM · MRK · NVS
🕰️ Price × news · engine report card
Drag to pan, scroll to zoom · real daily bars and volume
📜 Call history (newest first
12 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view
Sign up · free 7-day trial →Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.
Sign up · free 7-day trial →